Gadoteric Acid 0.5mmol/mL

Dotarem® was first developed in 1989 with the aim of minimizing the release risk of gadolinium. It is the first macrocyclic and ionic gadolinium-based contrast agent approved in the USA.

Indications:
Nuclear magnetic resonance imaging:

  • Neuroradiology: tumour of the spine and the surrounding tissues, intracranial tumours.
  • Abdominal radiology: primary and secondary tumours.
  • Primary tumour of the bone and soft tissues.

Presentation: Box of 1 vial of 10mL

Storage: Do not store above 30°C

Interested in these products?

Contact us to find out more